Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2019-10-20 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
CF33 Oncolytic Virus Clinical Trial Program Update 3 pages 87.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on the clinical trial program for the CF33 oncolytic virus technology. It discusses planned Phase 1 clinical trials, preclinical study results, and references to scientific publications. There is no financial data, earnings information, or regulatory filing of financial results. The document is not a report itself but an announcement about clinical development plans and shareholder meeting information. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement related to clinical trial updates and shareholder meeting notice, best classified under Regulatory Filings (RNS). The document length is 7,561 characters, which is substantial but the content is clearly an announcement rather than a full report or transcript.
2019-10-20 English
Change of Director's Interest Notice - AH 4 pages 279.7KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement dated 21 October 2019 regarding a Non-Executive Director, Dr Axel Hoos, increasing his shareholding following the exercise of options. It includes detailed information about the director's change in securities holdings, referencing Appendix 3Y, which is a standard form for notifying changes in directors' interests in securities under ASX listing rules. The content focuses on the director's personal share transactions and changes in ownership, not on financial results, management changes, or other report types. Therefore, this document fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a detailed notification of insider trading activity.
2019-10-20 English
Appendix 3B and 708A Notice 14 pages 500.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of securities issued, exercise of options, issue prices, and compliance with ASX rules. It includes sections on the class of securities, issue price, purpose of the issue, security holder approvals, and quotation agreements. The document is a formal announcement related to the issuance and quotation of additional securities on the Australian Securities Exchange (ASX). It does not contain financial statements, management discussion, or earnings data, nor is it a report or transcript. The content aligns with announcements about new share issues and capital changes. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial (15,000 characters), indicating it is the announcement itself, not a brief notice or report publication announcement.
2019-10-17 English
Yuman Fong, MD to Chair Imugene Oncolytic Virotherapy SAB 3 pages 134.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement about the appointment of a new Chair for the Oncolytic Virotherapy Scientific Advisory Board at Imugene Limited. It discusses the background of the appointee, the scientific context of the company's work, and mentions a forthcoming shareholder approval at an Extraordinary General Meeting (EGM). There are no financial statements, earnings data, or detailed financial analysis present. The document is primarily an announcement of a management/scientific advisory board appointment and related corporate news. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing or a report publication announcement. The best fitting category is Board/Management Information (MANG), as it announces a key appointment to the company's scientific advisory board, which is part of senior management or governance-related information.
2019-10-16 English
Notice of Extraordinary General Meeting/Proxy Form 89 pages 1.9MB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Extraordinary General Meeting (EGM) for Imugene Limited, including detailed resolutions for shareholder approval related to the acquisition of Vaxinia Pty Ltd and issuance of shares as consideration. It contains the Notice of Meeting, explanatory memorandum, voting exclusions, and background information on the transaction and related parties. The content is focused on soliciting shareholder approval for specific corporate actions and includes proxy voting instructions. There is no financial statement, earnings data, or audit information presented. The document is not a report itself but a meeting notice and explanatory material for shareholder decision-making. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2019-10-13 English
Notice of UMP Facility to Eligible Shareholders 1 p
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement titled 'NOTICE OF SHARE SALE FACILITY FOR HOLDERS OF UNMARKETABLE PARCELS TO ELIGIBLE SHAREHOLDERS'. It discusses the establishment and terms of a facility allowing shareholders with small parcels of shares to sell them. The content is an announcement about a share sale facility, including key dates and clarifications, but does not contain financial statements, management discussion, or detailed financial data. The document length is short (1604 characters), and it is clearly an announcement rather than a full report or financial filing. This fits the category of Share Issue/Capital Change announcements, as it relates to share sale facilities and shareholder share parcels. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2019-10-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.